Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Rubicon ResearchNSE:RUBICON +1.45%18 EBITDA Margin % is 23.61% as of Mar. 2026, which is 15% above its 10-year median of 20.60. GuruFocus rates NSE:RUBICON with a GF Score™ of 18/100. The stock has 3 warning signs investors should review. Among 960 Drug Manufacturers companies, Rubicon Research ranks better than 75.62% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Rubicon Research's EBITDA for the
three
months ended in Mar. 2026 was ₹1,213 Mil. Rubicon Research's Revenue for the
three
months ended in Mar. 2026 was ₹5,139 Mil. Therefore, Rubicon Research's EBITDA margin for the quarter that ended in Mar. 2026 was 23.61%.
Rubicon Research (NSE:RUBICON) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Rubicon Research EBITDA Margin % Related Terms
Rubicon Research EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Rubicon Research's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:RUBICON vs LLY, JNJ, ABBV: EBITDA Margin % Comparison
For the Drug Manufacturers - General subindustry, Rubicon Research's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rubicon Research EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Rubicon Research's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Rubicon Research's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rubicon Research (NSE:RUBICON) has a EBITDA Margin % of 23.61% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Rubicon Research and its competitors. This is 15% above median its historical median of 20.60. Over the past decade, Rubicon Research's EBITDA Margin % has ranged from 10.81 to 23.28. According to the industry distribution chart, Rubicon Research ranks #234 out of 960 companies in the Drug Manufacturers industry, placing it in the top 24.4%.
Is Rubicon Research's EBITDA Margin % too high?
Rubicon Research's current EBITDA Margin % of 23.61% is 15% above median its 10-year median of 20.60. Over the past 10 years, this metric has ranged from a low of 10.81 to a high of 23.28. The Drug Manufacturers industry median EBITDA Margin % is 12.52. Rubicon Research's value of 23.61% is 88.7% above this industry median. Based on the distribution chart, Rubicon Research ranks #234 out of 960 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Rubicon Research has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Rubicon Research's EBITDA Margin % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Rubicon Research ranks #234 out of 960 companies for EBITDA Margin %. This places Rubicon Research in the top 24% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 12.52. Rubicon Research's value of 23.61% is 88.7% above this benchmark. Historically, Rubicon Research's own EBITDA Margin % has ranged from 10.81 to 23.28 over the past decade. While the company's 10-year median is 20.60 vs. the industry median of 12.52, Rubicon Research has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.52, based on 960 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Rubicon Research's current EBITDA Margin % of 23.61% is 88.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Rubicon Research and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rubicon Research's current EBITDA Margin % is 23.61%, which is 15% above median its own 10-year median of 20.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rubicon Research stock overvalued right now?
Rubicon Research (NSE:RUBICON) has a current EBITDA Margin % of 23.61%. The current EBITDA Margin % is 23.61%, which is 15% above median its 10-year median of 20.60 and 88.7% above the Drug Manufacturers industry median of 12.52. Rubicon Research's overall GF Score™ is 18/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Rubicon Research (NSE:RUBICON), the current EBITDA Margin % is 23.61% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Rubicon Research Ltd is a pharmaceutical formulations company specializing in developing, manufacturing, and marketing branded specialty and generic prescription products. Starting as a provider of contract formulation development services, the company expanded to operate an oral solids manufacturing facility in India, offering contract development and manufacturing services for regulated markets. The company's diverse product portfolio covers multiple therapeutic areas, including analgesics and pain management, CVS, CNS, hypokalemia, skeletal muscle relaxants, NRT, gastrointestinal, metabolic, and immunosuppressants. The company operates in India, the USA, and other markets, with the majority of its revenue coming from the USA.
18GF Score
Get the complete analysis for NSE:RUBICON
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:RUBICON has been successfully added to your 
